Due to observations that M2-like CD163+ TAMs were associated with poor prognosis in HNSCC, breast, gastric, colorectal and hepatocellular cancers, this study investigated whether CD163+ TAMs could also be adopted as a prognostic indicator in OSCC. This evidence concerns the gene CD163 and hepatocellular carcinoma.